These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 31209157

  • 1. Going After METex14 in NSCLC.
    Cancer Discov; 2019 Aug; 9(8):OF9. PubMed ID: 31209157
    [Abstract] [Full Text] [Related]

  • 2. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
    Wu YL, Smit EF, Bauer TM.
    Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
    [Abstract] [Full Text] [Related]

  • 3. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
    Huang C, Zou Q, Liu H, Qiu B, Li Q, Lin Y, Liang Y.
    Curr Treat Options Oncol; 2020 Apr 18; 21(4):33. PubMed ID: 32306194
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
    Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV.
    J Hematol Oncol; 2021 Aug 23; 14(1):129. PubMed ID: 34425853
    [Abstract] [Full Text] [Related]

  • 5. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T, Liang Y, Zhu V, Ou SI.
    Lung Cancer; 2017 Jan 23; 103():27-37. PubMed ID: 28024693
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.
    Reale ML, Passiglia F, Cappuzzo F, Minuti G, Occhipinti M, Bulotta A, Delmonte A, Sini C, Galetta D, Roca E, Pelizzari G, Cortinovis D, Gariazzo E, Pilotto S, Citarella F, Bria E, Muscolino P, Pozzessere D, Carta A, Pignataro D, Calvetti L, Leone F, Banini M, Di Micco C, Baldini E, Favaretto A, Malapelle U, Novello S, Pasello G, Tiseo M.
    ESMO Open; 2024 Sep 23; 9(9):103680. PubMed ID: 39214048
    [Abstract] [Full Text] [Related]

  • 8. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM.
    J Thorac Oncol; 2017 Jan 23; 12(1):137-140. PubMed ID: 27666659
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
    Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS, GEOMETRY mono-1 Investigators.
    N Engl J Med; 2020 Sep 03; 383(10):944-957. PubMed ID: 32877583
    [Abstract] [Full Text] [Related]

  • 11. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA, Geurts-Giele WRR, von der TJH, Meijssen IC, Dinjens WNM, Aerts JGJV, Dingemans AMC, Lolkema MP, Paats MS, Dubbink HJ.
    Lung Cancer; 2020 Feb 03; 140():46-54. PubMed ID: 31862577
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Cortot A, Le X, Smit E, Viteri S, Kato T, Sakai H, Park K, Camidge DR, Berghoff K, Vlassak S, Paik PK.
    Clin Lung Cancer; 2022 May 03; 23(3):195-207. PubMed ID: 35272955
    [Abstract] [Full Text] [Related]

  • 14. [MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
    Baldacci S, Kherrouche Z, Descarpentries C, Wislez M, Dansin E, Furlan A, Tulasne D, Cortot AB.
    Rev Mal Respir; 2018 Oct 03; 35(8):796-812. PubMed ID: 30174236
    [Abstract] [Full Text] [Related]

  • 15. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
    Choi W, Park SY, Lee Y, Lim KY, Park M, Lee GK, Han JY.
    Cancer Res Treat; 2021 Oct 03; 53(4):1024-1032. PubMed ID: 33540494
    [Abstract] [Full Text] [Related]

  • 16. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
    Blanc-Durand F, Alameddine R, Iafrate AJ, Tran-Thanh D, Lo YC, Blais N, Routy B, Tehfé M, Leduc C, Romeo P, Stephenson P, Florescu M.
    Oncologist; 2020 Nov 03; 25(11):916-920. PubMed ID: 32716573
    [Abstract] [Full Text] [Related]

  • 17. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Mazieres J, Vioix H, Pfeiffer BM, Campden RI, Chen Z, Heeg B, Cortot AB.
    Clin Lung Cancer; 2023 Sep 03; 24(6):483-497. PubMed ID: 37451931
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
    Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas VR, Wolff AM, Fraser JS, Collisson EA, McCoach CE, Camidge DR, Pacheco J, Bazhenova L, Li T, Bivona TG, Blakely CM.
    Clin Cancer Res; 2020 Jan 15; 26(2):439-449. PubMed ID: 31548343
    [Abstract] [Full Text] [Related]

  • 20. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
    Tseng LW, Chang JW, Wu CE.
    Int J Mol Sci; 2022 Oct 05; 23(19):. PubMed ID: 36233109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.